Theravance Biopharma (TBPH) Tops Q1 EPS by 4c

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.22), $0.04 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $6.43 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Citi cuts Domino's Pizza price target to $335 amid weak sales
• Piper Sandler Reiterates Overweight Rating on Henry Schein (HSIC)